pagoclone
Phase 2Small molecule
Endo Pharmaceuticalspagoclone is one of 31 small molecule programs targeting Stuttering. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
38 competitors in Premature Ejaculation
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Cialis
Eli LillyPhase 3
Paxil
SSebela Pharmaceuticals Development LLC
Phase 3
Restasis
TTaiwan Bio Therapeutics Inc.
Phase 3
Ultram
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Botox
AbbViePhase 3
Rapaflo
AbbViePhase 2
Anafranil
SSpecgx
Phase 3
Standard Treatment
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pagoclone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company